# A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma

> **NCT02539537** · PHASE3 · COMPLETED · sponsor: **UNICANCER** · enrollment: 171 (actual)

## Conditions studied

- Pancreatic Cancer
- Carcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Folinic Acid
- **DRUG:** 5-Fluoro-uracil
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan
- **DRUG:** L-folinic

## Key facts

- **NCT ID:** NCT02539537
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-23
- **Primary completion:** 2022-02
- **Final completion:** 2023-09-25
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2024-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02539537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02539537, "A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02539537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*